Navellier & Associates Inc cut its stake in Merck & Co., Inc. (NYSE:MRK) by 8.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,101 shares of the company’s stock after selling 1,099 shares during the period. Navellier & Associates Inc’s holdings in Merck & Co., Inc. were worth $735,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Clearwater Capital Advisors LLC acquired a new stake in Merck & Co., Inc. during the first quarter valued at approximately $103,000. SRS Capital Advisors Inc. lifted its stake in Merck & Co., Inc. by 208.4% during the first quarter. SRS Capital Advisors Inc. now owns 1,983 shares of the company’s stock valued at $108,000 after purchasing an additional 1,340 shares during the last quarter. Taylor Wealth Management Partners acquired a new stake in Merck & Co., Inc. during the second quarter valued at approximately $110,000. Creative Financial Designs Inc. ADV lifted its stake in Merck & Co., Inc. by 155.2% during the second quarter. Creative Financial Designs Inc. ADV now owns 1,832 shares of the company’s stock valued at $111,000 after purchasing an additional 1,114 shares during the last quarter. Finally, Well Done LLC acquired a new stake in Merck & Co., Inc. during the first quarter valued at approximately $115,000. Institutional investors and hedge funds own 72.19% of the company’s stock.

In other Merck & Co., Inc. news, VP Rita A. Karachun sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 2nd. The shares were sold at an average price of $65.01, for a total value of $325,050.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sanat Chattopadhyay sold 29,208 shares of the stock in a transaction that occurred on Friday, August 3rd. The stock was sold at an average price of $65.20, for a total transaction of $1,904,361.60. Following the completion of the sale, the insider now owns 70,675 shares of the company’s stock, valued at approximately $4,608,010. The disclosure for this sale can be found here. In the last quarter, insiders sold 396,393 shares of company stock valued at $25,235,061. Insiders own 0.32% of the company’s stock.

Shares of NYSE:MRK opened at $69.98 on Friday. Merck & Co., Inc. has a 52 week low of $52.83 and a 52 week high of $70.94. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.33 and a quick ratio of 1.04. The company has a market capitalization of $188.36 billion, a P/E ratio of 16.63, a PEG ratio of 2.41 and a beta of 0.81.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Friday, July 27th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.03. Merck & Co., Inc. had a net margin of 3.67% and a return on equity of 32.68%. The company had revenue of $10.47 billion during the quarter, compared to the consensus estimate of $10.28 billion. During the same quarter in the prior year, the firm earned $1.01 EPS. The company’s revenue was up 5.4% compared to the same quarter last year. research analysts expect that Merck & Co., Inc. will post 4.27 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, October 5th. Shareholders of record on Monday, September 17th will be given a $0.48 dividend. The ex-dividend date of this dividend is Friday, September 14th. This represents a $1.92 dividend on an annualized basis and a yield of 2.74%. Merck & Co., Inc.’s payout ratio is 48.24%.

Several analysts recently commented on MRK shares. Bank of America increased their target price on shares of Merck & Co., Inc. from $70.00 to $74.00 and gave the company a “buy” rating in a research note on Monday, July 30th. Morgan Stanley set a $74.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, August 23rd. Jefferies Financial Group restated a “hold” rating and issued a $59.00 price target on shares of Merck & Co., Inc. in a research report on Sunday, July 15th. Zacks Investment Research upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $69.00 price target for the company in a research report on Thursday, June 7th. Finally, SunTrust Banks restated a “buy” rating and issued a $77.00 price target on shares of Merck & Co., Inc. in a research report on Thursday, August 16th. Six investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $67.93.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Read More: Should you buy a closed-end mutual fund?

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.